Veracyte, Inc. (NASDAQ: VCYT) is a global diagnostics company specializing in genomic tests for cancer care. It develops and commercializes molecular diagnostics that provide clinicians with actionable insights to resolve diagnostic uncertainty, guide treatment decisions, and improve patient outcomes, primarily targeting cancers like thyroid, prostate, and others.[1][2] Serving endocrinologists, surgeons, oncologists, and patients worldwide, Veracyte addresses key challenges in cancer diagnosis—such as avoiding unnecessary surgeries and personalizing therapies—through its Veracyte Diagnostics Platform, which leverages broad genomic data, AI-assisted analysis, and clinical evidence generation.[2] The company has tested over 800,000 patients, operates CLIA-certified labs, and is expanding via centralized U.S. testing and distributed IVDs for global markets, demonstrating strong growth through product launches like the Decipher Prostate Metastatic Test.[2][5]
Founded in 2004, Veracyte emerged as a pioneer in genomic diagnostics, harnessing expertise in genomic technology and machine learning to tackle unmet needs in cancer care.[5] The company started with innovations like the Afirma Genomic Sequencing Classifier for thyroid cancer diagnosis, processing patient samples in centralized labs to deliver clinically validated results that reduce diagnostic ambiguity.[1] Early traction came from proprietary classifiers, payer contracts, and a growing genomic database, enabling R&D expansion; pivotal moments include scaling to over 900 employees across San Francisco and Austin, and operational upgrades like NetSuite for data-driven decisions that cut reporting time by days, fueling patient-focused growth.[4][5]
Veracyte rides the precision oncology wave, where genomic testing and AI converge to shift cancer care from reactive to proactive, reducing overtreatment amid rising global cancer rates.[2] Timing aligns with advances in multi-omics and machine learning, amplified by post-pandemic demand for non-invasive diagnostics and payer support for validated tests.[1][4] Market forces like expanding IVD regulations and collaborative evidence generation favor its model, influencing the ecosystem by advancing scientific understanding, enabling personalized therapies, and setting standards for data-rich diagnostics that empower clinicians worldwide.[2][5]
Veracyte is poised for acceleration through platform expansions, new test launches (e.g., metastatic prostate), and global IVD scaling, leveraging its data moat for AI enhancements and R&D.[2] Trends like AI diagnostics, multi-omics integration, and ESG-focused sustainability will shape its path, potentially amplifying influence in precision medicine.[2] As it builds on its mission to transform cancer care, Veracyte stands out as a diagnostics leader delivering real patient impact in a high-stakes field.[1]
Veracyte has raised $71.0M in total across 3 funding rounds.
Veracyte's investors include Access Biotechnology, Domain Associates, Kleiner Perkins, Versant Ventures, George Rehm.
Veracyte has raised $71.0M across 3 funding rounds. Most recently, it raised $28.0M Series C in June 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2013 | $28.0M Series C | Access Biotechnology, Domain Associates, Kleiner Perkins, Versant Ventures, George Rehm | |
| Sep 1, 2012 | $15.0M Venture Round | Access Biotechnology, Domain Associates, Kleiner Perkins, George Rehm | |
| Jun 1, 2010 | $28.0M Series B | Access Biotechnology, Domain Associates, Kleiner Perkins, Versant Ventures, George Rehm |
